Isotopia Molecular Imaging

Company Overview

Snapshot

Founded in February 2007 by Eli Shalom, Isotopia Molecular Imaging operates with 51–200 employees. The company has raised $3.75 million across one funding round from Metrontario. In May 2025, Isotopia Molecular Imaging partnered with Cardirad to launch Isoprotrace in Sweden and Denmark, expanding access to advanced prostate cancer imaging.

Business overview

Isotopia Molecular Imaging is a global pharmaceutical company focused on developing, producing, and distributing diagnostic and therapeutic radioactive isotopes, including advanced PET and SPECT radiotracers. Its core technology centers on radioisotopes like Lutetium-177 (C.A and N.C.A), which shows promise in treating late-stage cancers such as metastatic prostate cancer and neuroendocrine tumors. The company also offers products like Isoprotrace and PSMA, serving hospitals, pharma companies, and healthcare providers within the Health Tech & Life Sciences sector, with a focus on cancer diagnostics and therapy.

Strategic signal

Isotopia Molecular Imaging is actively expanding its market reach for advanced radiopharmaceuticals. The company's launch of Isoprotrace in Germany in March 2025, followed by its expansion into Sweden and Denmark in May 2025, indicates a strategic focus on commercializing its prostate cancer imaging solutions across key European markets. This signals a strong push towards broader adoption and revenue growth for its diagnostic products.

Company Intelligence Q&A

What is Isotopia Molecular Imaging's primary focus?

Isotopia Molecular Imaging develops, produces, and distributes diagnostic and therapeutic radioactive isotopes and advanced PET and SPECT radiotracers, primarily for cancer treatment and imaging.

Which key product is central to Isotopia Molecular Imaging's cancer therapy efforts?

Isotopia Molecular Imaging's flagship product, the radioisotope Lutetium-177 (both C.A and N.C.A), is being developed for treating various late-stage cancers, including metastatic prostate cancer and neuroendocrine tumors.

What was a significant commercial launch for Isotopia Molecular Imaging?

In March 2025, Isotopia Molecular Imaging officially launched Isoprotrace in Germany in partnership with DSD Pharma, expanding access to advanced prostate cancer imaging.

Has Isotopia Molecular Imaging expanded its Isoprotrace product beyond Germany?

Yes, in May 2025, Isotopia Molecular Imaging, in partnership with Cardirad, announced the launch of Isoprotrace in Sweden and Denmark, further expanding access to advanced prostate cancer imaging.

What strategic agreement did Isotopia Molecular Imaging enter into regarding the supply of Gadolinium-160?

In January 2025, Kinectrics and Isotopia Molecular Imaging announced an agreement for Kinectrics to supply Gadolinium-160 (Gd-160) to support the production of Terbium-161 (Tb-161) for advanced radiotherapeutics.